261 related articles for article (PubMed ID: 26114496)
21. Clinical utilization of serum- or plasma-based miRNAs as early detection biomarkers for pancreatic cancer: A meta-analysis up to now.
Wei L; Yao K; Gan S; Suo Z
Medicine (Baltimore); 2018 Aug; 97(35):e12132. PubMed ID: 30170450
[TBL] [Abstract][Full Text] [Related]
22. Effects of miR-16 plus CA19-9 detections on pancreatic cancer diagnostic performance.
Gao L; He SB; Li DC
Clin Lab; 2014; 60(1):73-7. PubMed ID: 24600978
[TBL] [Abstract][Full Text] [Related]
23. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
24. [miRNA-192, miRNA-21 and miRNA-200: new pancreatic cancer markers in diabetic patients?].
Škrha P; Hořínek A; Anděl M; Škrha J
Vnitr Lek; 2015 Apr; 61(4):351-4. PubMed ID: 25894267
[TBL] [Abstract][Full Text] [Related]
25. Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma.
Murali Manohar K; Sasikala M; Kvsrr Y; Sunil V; Talukdar R; Murthy H; Ramji C; Rao GV; Pradeep R; Reddy DN
Tumour Biol; 2017 Mar; 39(3):1010428317695018. PubMed ID: 28351309
[TBL] [Abstract][Full Text] [Related]
26. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer.
Le Large TY; Meijer LL; Prado MM; Kazemier G; Frampton AE; Giovannetti E
Expert Rev Mol Diagn; 2015; 15(12):1525-9. PubMed ID: 26567751
[TBL] [Abstract][Full Text] [Related]
27. Dysregulated Serum MiRNA Profile and Promising Biomarkers in Dengue-infected Patients.
Ouyang X; Jiang X; Gu D; Zhang Y; Kong SK; Jiang C; Xie W
Int J Med Sci; 2016; 13(3):195-205. PubMed ID: 26941580
[TBL] [Abstract][Full Text] [Related]
28. Plasma miR-15b-5p, miR-338-5p, and miR-764 as Biomarkers for Hepatocellular Carcinoma.
Chen Y; Chen J; Liu Y; Li S; Huang P
Med Sci Monit; 2015 Jun; 21():1864-71. PubMed ID: 26119771
[TBL] [Abstract][Full Text] [Related]
29. Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer.
Tavano F; Gioffreda D; Valvano MR; Palmieri O; Tardio M; Latiano TP; Piepoli A; Maiello E; Pirozzi F; Andriulli A
Sci Rep; 2018 Nov; 8(1):16389. PubMed ID: 30401891
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of circulating lipocalins and insulin-like growth factor axis in pancreatic cancer diagnosis.
El-Mesallamy HO; Hamdy NM; Zaghloul AS; Sallam AM
Pancreas; 2013 Jan; 42(1):149-54. PubMed ID: 22617715
[TBL] [Abstract][Full Text] [Related]
32. Identification of Circulating Serum miRNAs as Novel Biomarkers in Pancreatic Cancer Using a Penalized Algorithm.
Lee J; Lee HS; Park SB; Kim C; Kim K; Jung DE; Song SY
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498271
[TBL] [Abstract][Full Text] [Related]
33. Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus.
Dai X; Pang W; Zhou Y; Yao W; Xia L; Wang C; Chen X; Zen K; Zhang CY; Yuan Y
J Diabetes; 2016 May; 8(3):422-33. PubMed ID: 25991015
[TBL] [Abstract][Full Text] [Related]
34. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
[TBL] [Abstract][Full Text] [Related]
35. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
36. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy.
Fang L; Ellims AH; Moore XL; White DA; Taylor AJ; Chin-Dusting J; Dart AM
J Transl Med; 2015 Sep; 13():314. PubMed ID: 26404540
[TBL] [Abstract][Full Text] [Related]
37. Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs.
Kim K; Yoo D; Lee HS; Lee KJ; Park SB; Kim C; Jo JH; Jung DE; Song SY
BMC Med Genomics; 2019 May; 12(1):62. PubMed ID: 31096984
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer.
Mohamed AA; Soliman H; Ismail M; Ziada D; Farid TM; Aref AM; Al Daly ME; Abd Elmageed ZY
Pancreatology; 2015; 15(1):34-9. PubMed ID: 25464937
[TBL] [Abstract][Full Text] [Related]
39. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma.
Fang Z; Tang J; Bai Y; Lin H; You H; Jin H; Lin L; You P; Li J; Dai Z; Liang X; Su Y; Hu Q; Wang F; Zhang ZY
J Exp Clin Cancer Res; 2015 Aug; 34(1):86. PubMed ID: 26297223
[TBL] [Abstract][Full Text] [Related]
40. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
